COVID-19 has been the ultimate big pharma catalyst, as well as the biggest thing to hit biopharmaceutical news pages in decades. On the industry side, however, investors and observers remain mindful of non-COVID-related trends in biopharma. More accurately, trends well underway in January still deserve attention.  2020 Biopharma Trends to Keep an Eye On These…

Read More

It’s no wonder scientists begin clinical trials with great excitement: combine promising discoveries with the best test sites, scientists, and as many qualified, willing patients as possible, and off you go to hypothesis validation.  Along the way, however, even the best drugs and devices hit roadblocks.  Like a manned space mission, every clinician needs near-flawless…

Read More
Woman working in a life sciences lab

Today, with the FDA endorsing fewer new treatments, life sciences companies are pressured to develop better therapies while also struggling to control costs and retain their star employees. And while some companies solve problems with more resources, more staff, and more funding, the answer for others is less. First used in the auto industry, “lean…

Read More

In the latest PMI report Pulse of the Profession 2020 (2020), 11.4% of surveyed organizations attribute investment waste to poor project performance.  What defines project performance and ultimately its success is the completion of the intended goals on time and within budget. As simple as it sounds, organizations still fail in many of their programs…

Read More

Drug and medical device development and manufacturing is a complex process that involves multiple supply chains, various monitoring systems, and countless players from R&D to market. Due to the sensitive nature of the products and the repercussions should anything go awry during production or distribution, the medical industry is under constant pressure for attention to…

Read More

In 2017, R&D investments in the pharmaceutical space reached more than $70 billion, with projected figures of over $200 billion by 2024. Pharma is one of the two sectors with semiconductors that are heavily reinvesting its revenue in research and development (15% to 20% on average). Considering the cost explosion of developing a new drug…

Read More

Spending on prescription drugs in the United States is expected to reach $600 billion by 2023. The continuously increasing need for pharmaceuticals is mostly driven by an aging population, a rise in chronic pathologies, and lifestyle changes that lead to poorer health. In this highly competitive landscape, a few giants dominate the industry, leaving a…

Read More

What Have We Learned? Any emergency or unplanned event requires proactive and prepared leadership to manage a rapidly evolving, unstable situation. This leadership must have a structured, current, and comprehensive disaster preparedness strategy that addresses core mitigation areas. This leadership must also engage individuals who have a clear command of core Project Management principles to…

Read More

The landscape of clinical trials and other clinical development projects has dramatically changed in recent years. Progress made in scientific discovery is paving the way to novel therapies and compounds that seek to surpass existing drugs in efficacy and safety.  But, innovation is not the only competitive driver. Concerns over an ageing population and increased…

Read More

New drug development is a costly, lengthy and risky process. Hurdles spring up at every stage and today’s landscape puts sponsors under more pressure than ever before. Clinical trials are becoming increasingly complex, regulatory bodies increasingly demanding, and stakeholders increasingly scrutinous.  Considering the resources invested in R&D, managing everyone involved internally and externally for years…

Read More